StockpollyBeta
Get App
Popularity #1,106
INBX · NASDAQ · Biotechnology

Inhibrx Biosciences (INBX)

Develops biologic drug candidates led by ozekibart and INBRX-106.

$100.88
vs last close−9.79 (−8.85%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue020000010000
Cost of revenue000011111110
Gross profit0100−1−1−11−1−1−10
4690731614649422833303032
Research & development388264683833372229252524
881093817665668
Selling & marketing000000000000
General & administrative881093817665668
Other expenses00000−1−1−1−1−100
Operating income−46−88−74−161−47−50−43−27−34−31−31−32
−6−5−52,019320−1−1−2−3−4
Interest income253332222111
Interest expense888500333346
Other non-operating income−20−3−2,024−3−2−2−2−2−1−1−1
Income before tax−52−94−791,858−44−48−43−29−35−33−33−37
Income tax expense000000000000
Net income from continuing operations−52−94−791,858−44−48−43−29−35−33−33−37
Net income−52−94−791,858−44−48−43−29−35−33−33−37
EPS, basic−$1.10−$1.73−$1.44$127.10−$2.84−$3.31−$2.80−$1.85−$2.28−$2.11−$2.15−$2.34
EPS, diluted−$1.10−$1.73−$1.44$125.48−$2.84−$3.31−$2.80−$1.85−$2.28−$2.11−$2.15−$2.34
Weighted average shares, basic475455151514151515151616
Weighted average shares, diluted475455151514151515151616
EBITDA−43−88−701,863−43−47−40−25−31−29−29−30
Depreciation & amortization000011111111
EBIT−44−88−711,863−44−48−41−26−32−30−30−31